Ocular Therapeutix Q3 net loss $69.4M; SOL-R hits 555 subjects; cash ~$790M with offering

OCULAR THERAPEUTIX, INC

2025-Q3 EPS reported -$1.15 revenue$38,701,000

Net loss $(69.4)M ($0.38 loss per share) vs $(36.5)M loss in Q3 2024; revenue $14.5M, down 5.8% YoY.
SOL-R registrational trial in wet AMD achieved target randomization of 555 subjects; topline data on track for 1H 2027.
Cash balance $344.8M at Sep 30, plus ~$445M net proceeds from Oct equity offering providing runway into 2028.
HELIOS Phase 3 program for AXPAXLI in NPDR to start imminently using novel DRSS endpoint.
R&D expenses rose to $52.4M from $37.1M due to clinical trial costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.